Vol. 33

Index/Contents

2006

ELSEVIER
SAUNDERS

Obstet Gynecol Clin N Am
33 (2006) 631–635

OBSTETRICS AND
GYNECOLOGY
CLINICS
OF NORTH AMERICA

Index

Note: Page numbers of article titles are in **boldface** type.

A

Alcohol intake, and sexual dysfunction, 607

Alpha-adrenergic drugs, and sexual dysfunction, 604

Amphetamines, and sexual dysfunction, 608

Androgen insufficiency, female. *See* Female androgen insufficiency.

Androgens, for sexual dysfunction, due to medication side effects, 611–612

Antianxiety drugs, and sexual dysfunction, 606

Antidepressants
and sexual dysfunction, 605–606
for sexual dysfunction, due to medication side effects, 613

Antiepileptic drugs, and sexual dysfunction, 605

Antihypertensive drugs, and sexual dysfunction, 604–605

Antipsychotic drugs, and sexual dysfunction, 606

Apomorphine, for sexual dysfunction, due to medication side effects, 613

B

Basson, contributions of, to study of sexual response, 520–523, 553–555

Benzodiazepines, and sexual dysfunction, 606

Brief Sexual Symptom Checklist, in sexual history taking, 545

Bupropion
and sexual dysfunction, 606
for sexual dysfunction, due to medication side effects, 613

C

Cervical cancer, sexual dysfunction after, 623–624, 626

Clitoral devices
for female androgen insufficiency, 597
for orgasmic dysfunction, 584–585
for sexual dysfunction, after gynecologic cancer, 626

Clonidine, and sexual dysfunction, 604

Cocaine, and sexual dysfunction, 608

Cognitive behavioral therapy
for dyspareunia, 575
for hypoactive sexual desire disorder, 561
for orgasmic dysfunction, 584

Combined oral contraceptives, and sexual dysfunction, 600

Contact dermatitis, dyspareunia treatments and, 573

Contraceptives, and sexual dysfunction, 600, 604

Cotton swab test, in diagnosis, of dyspareunia, 572

D

Dehydroepiandrosterone
for female androgen insufficiency, 595
for sexual dysfunction, due to medication side effects, 611–612

Dehydroepiandrosterone sulfate, for sexual dysfunction, due to medication side effects, 611–612

Dehydroepiandrosterone sulfate assays, in diagnosis, of female androgen insufficiency, 595

Depo-medroxyprogesterone acetate, and sexual dysfunction, 600, 604

Depression
and hypoactive sexual desire disorder, 558
and orgasmic dysfunction, 581

Dermatitis, contact, dyspareunia treatments and, 573

0889-8545/06/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/S0889-8545(06)00091-X

Digital vaginal examination, for dyspareunia, 572

Domestic violence, and hypoactive sexual desire disorder, 558

Duloxetine, and sexual dysfunction, 605–606

Dyspareunia, **565–577**
and hypoactive sexual desire disorder, 557
characteristics of, 566–567
definition of, 532, 566–567
diagnosis of, 569–572
cotton swab tests in, 572
digital vaginal examination in, 572
patient history in, 569–571
physical examination in, 571–572
saline and potassium hydroxide wet smears in, 572
endometriosis and, 567
fungal infections and, 568
management of, 572–575
cognitive behavioral therapy in, 575
pharmacologic, 573
and contact dermatitis, 573
surgical, 572–574
vestibulectomy, 574
vestibuloplasty, 574
pathophysiology of, 567–569
physical conditions associated with, 571
prevalence of, 565–566
psychologic factors in, 568–569
Sjögren syndrome and, 571
vaginismus and, 566–567, 569, 570–571, 574–575

E

Endometriosis, and dyspareunia, 567

EROS-CTD device, for orgasmic dysfunction, 584–585

Estrogen
for sexual dysfunction, due to medication side effects, 609–610
in sexual response, 529
with methyl testosterone, for sexual dysfunction, due to medication side effects, 611

F

Female androgen insufficiency, 529, 551, **589–598**
after oophorectomy, 591–592, 624
aging and, 592–593
androgen production and metabolism, 590–591
decision-making algorithm for, 594–595
diagnosis of, 593–595
challenges in, 597
etiology of, 591
hypopituitarism and, 592
management of, 595–597
and virilization, 596
challenges in, 597
clitoral devices in, 597
dehydroepiandrosterone in, 595
testosterone therapy in, 596
menopause and, 592–593
pathophysiology of, 591–592
signs and symptoms of, 593

Fungal infections, and dyspareunia, 568

G

Gonadotrophin releasing hormone agonists, and sexual dysfunction, 607

Gynecologic cancer, sexual dysfunction after, **621–630**
barriers to discussion of, 622
cancer treatments and, 622–623
oophorectomy, 624
cervical cancer, 623–624, 626
clitoral devices for, 626
diagnosis of, 627–628
hormone therapy for, 625–626
initiating discussion of, 627
ovarian cancer, 624, 625
PLISSIT model of sex therapy for, 627
prevalence of, 621–622
prevention of, 628–629
psychologic counseling for, 625
psychologic variables in, 625
psychosocial aspects of, 625
resources on, 629
vaginal dilator therapy for, 626

H

Hirsutism, transdermal testosterone and, 610–611

Hypoactive sexual desire disorder, **549–564**
American Foundation for Urologic Disease definition of, 557
definitions of, 531, 556, 557
depression and, 558
differential diagnosis of, 555–557
sexual arousal disorder, 557
sexual aversion disorder, 555
domestic violence and, 558
DSM definition of, 556
dyspareunia and, 557

evaluation of, 558–560
laboratory tests in, 560
patient history in, 558–560
physical examination in, 560
female androgen insufficiency and. *See* Female androgen insufficiency.
male partner sexual dysfunction and, 558
management of, 560–562
brief interventional therapy in, 561
cognitive behavioral therapy in, 561
counseling in, 561
intensive sex therapy in, 561
marital therapy in, 561
pharmacologic, 561–562
models of, 551–555
Basson, 553–555
biphasic, 552
Kaplan, 553
Masters and Johnson, 551–552
prevalence of, 549–550
risk factors for, 550–551
chronic illness, 550
decreased hormone levels, 551
substance abuse and, 558

Hypopituitarism, and female androgen insufficiency, 592

I

Illicit drugs, and sexual dysfunction. *See* Sexual dysfunction.

Infections, fungal, and dyspareunia, 568

Interferons, for dyspareunia, 573

Interventional therapy, for hypoactive sexual desire disorder, 561

K

Kaplan, contributions of, to study of sexual response, 519–520, 553

Kinsey, contributions of, to study of sexual response, 517

M

Male sexual dysfunction, and hypoactive sexual desire disorder, 558

Marijuana, and sexual dysfunction, 608

Marital therapy, for hypoactive sexual desire disorder, 561

Masters and Johnson, contributions of, to study of sexual response, 518–519, 551–552

Menopause, and female androgen insufficiency, 592–593

Methyl testosterone, with esterified estrogens, for sexual dysfunction, due to medication side effects, 611

N

Narcotics, and sexual dysfunction, 608

Neuropeptides, in sexual response, 529

Neurotransmitters, in sexual response, 529

O

Olanzapine, and sexual dysfunction, 606

Oophorectomy
female androgen insufficiency after, 591–592
sexual dysfunction after, 624

Orgasmic dysfunction, **579–587**
anatomic or medical problems and, 581
definition of, 532, 579–580
depression and, 581
epidemiology of, 580–582
evaluation of, 582–583
patient history in, 582–583
physical examination in, 583
management of, 583–585
clitoral devices in, 584–585
cognitive behavioral therapy in, 584
pharmacologic, 584–585
psychodynamic psychotherapy in, 584
systems theory in, 584
risk factors for, 581

Ovarian cancer, sexual dysfunction after, 624, 625

P

Paroxetine, and sexual dysfunction, 605–606

PDE 5 inhibitors, for sexual dysfunction, due to medication side effects, 612–613

PLISSIT model of sex therapy, for sexual dysfunction, after gynecologic cancer, 627

Potassium hydroxide wet smears, in diagnosis, of dyspareunia, 572

Progestin-only contraceptives, and sexual dysfunction, 600, 604

Psychoactive drugs, and sexual dysfunction, 605–606

Psychodynamic psychotherapy, for orgasmic dysfunction, 584

R

Recreational drugs, and sexual dysfunction. *See* Sexual dysfunction.

S

Saline wet smears, in diagnosis, of dyspareunia, 572

Selective serotonin reuptake inhibitors, and sexual dysfunction, 605–606

Sex hormone binding globulin
in androgen metabolism, 590–591
in diagnosis, of female androgen insufficiency, 594–595

Sex steroid hormones, in sexual response, 529

Sex therapy, for hypoactive sexual desire disorder, 561

Sexual arousal disorder
definition of, 531–532
versus hypoactive sexual desire disorder, 557

Sexual aversion disorder
definition of, 531
versus hypoactive sexual desire disorder, 555

Sexual dysfunction
after gynecologic cancer. *See* Gynecologic cancer.
categories of, **527–534**
dyspareunia. *See* Dyspareunia.
hypoactive sexual desire disorder. *See* Hypoactive sexual desire disorder.
orgasmic dysfunction. *See* Orgasmic dysfunction.
sexual arousal disorder, 531–532
sexual aversion disorder, 531
sexual pain disorders, 532
vaginismus, 532
clinical evaluation of, 532–533
medication side effects and, **599–620**
antiepileptic drugs, 605
antihypertensives, 604–605
contraceptives, 600, 604
combined oral contraceptives, 600
progestin-only drugs, 600, 604
gonadotrophin releasing hormone agonists, 607
illicit/recreational drugs, 607–608
alcohol, 607
amphetamines, 608
cocaine, 608
marijuana, 608
narcotics, 608
management of, 609–614
androgens in, 611–612
antidepressants in, 613
apomorphine in, 613
estrogen in, 609–610
historical aspects of, 609
PDE 5 inhibitors in, 612–613
transdermal testosterone in, 610–611
yohimbine in, 614
psychoactive drugs, 605–606
antianxiety drugs, 606
antidepressants, 605–606
antipsychotic drugs, 606
prevalence of, 527–528

Sexual function scales, in sexual history taking, 546

Sexual history, obtaining, **535–547**
barriers to discussing sexual health, 536–538
insufficient medical education or training, 537
lack of confidence, 537
lack of perceived treatment options, 538
patient discomfort, 538
time constraints, 537–538
underestimation of prevalence of dysfunction, 537
brief assessment in (2-3 minutes), 540–541
elements of history, 541–544
essential questions in, 544
gynecologic examination in, 542
importance of sexual health, 535–536
making environment conducive to, 539
medication side effects in, 542, 543
opportunities for, 539–540
rationale for, 546
referrals in, 546
scales, questionnaires, and checklists in, 545–546

Sexual response, **515–526,** 527
Basson model of, 520–523, 553–555
arousal, 521–522
limitations of, 523
reasons for engaging in sexual activity, 521
sexual satisfaction, 522
subjective arousal, 522–523
biologic factors in, 530–531
changing concepts of, 516–518

epidemiologic and survey studies of, 517
laboratory psychophysiologic studies of, 517
circular models of, 520–523
cultural and ethnic differences in, 516
definition of, 515
importance of, 515–516
Kaplan model of, 519–520, 553
laboratory studies of, 523–524
Masters and Johnson model of, 518–519, 551–552
mediators of, 529
neurotransmitters and neuropeptides, 529
sex steroid hormones, 529
physiology of, 528–529
psychosocial and interpersonal factors in, 531
scientific perspectives on, 516–518
scientific paradigms and animal models of, 517–518

Sildenafil, for sexual dysfunction, due to medication side effects, 612

Sjögren syndrome, and dyspareunia, 571

Substance abuse, and hypoactive sexual desire disorder, 558

Systems theory, for orgasmic dysfunction, 584

T

Testosterone levels, and sexual dysfunction. *See* Female androgen insufficiency.

Testosterone therapy
for female androgen insufficiency, 596
for sexual dysfunction
after gynecologic cancer, 626
due to medication side effects, 610–611

V

Vaginal dilator therapy, for sexual dysfunction, after gynecologic cancer, 626

Vaginal examination, for dyspareunia, 572

Vaginismus
and dyspareunia, 566–567, 569, 570–571, 574–575
definition of, 532

Vestibulectomy, for dyspareunia, 574

Vestibuloplasty, for dyspareunia, 574

Virilization
female androgen insufficiency treatments and, 596
transdermal testosterone and, 610

Vulvar vestibulitis syndrome, and dyspareunia. *See* Dyspareunia.

Y

Yohimbine, for sexual dysfunction, due to medication side effects, 614